Whole Genome Integrity Testing for Cancer:
Understanding changes in the cancer genome is crucial for determining treatment effectiveness and prognosis, particularly for targeted therapies. Currently, methods for detecting cancer genome variations include testing specific cancer-associated genes, analyzing all cancer-related gene mutations, examining protein-coding gene variations (whole exome sequencing), and assessing the entire genome (whole genome sequencing). Each approach has its pros and cons; for example, whole exome and whole genome sequencing are complex and costly, which has limited their routine clinical application. However, in the last 2-3 years, significant advancements in cost reduction, analysis capabilities, and processing speed have enabled many prominent medical centers to routinely apply these methods for detecting cancer genome variations, providing valuable information for treating patients. Our company leverages an advanced analysis system to rapidly assess cancer genome changes, providing essential information for targeted cancer therapy. Additionally, by utilizing a proprietary herbal medicine database and innovative search algorithms, we identify effective herbal treatments, integrating traditional Chinese and Western medicine to enhance cancer treatment efficacy and the chance of recovery.
Target Audience for Whole Genome Integrity Testing for Cancer:
Since this test uses cancer tissue samples with sequencing depth at least twice that of blood samples (at least 60X), it enables the analysis of both inherited genomic variations and cancer-specific mutations. By simultaneously performing transcriptome analysis of cancerous and surrounding normal tissues, we gain a clearer view of individual cancer characteristics, facilitating the formulation of more effective treatment strategies. This testing is suitable for:
1. Cancer patients seeking a comprehensive understanding of their cancer genome changes for more precise treatment and tailored herbal medicine options.
2. Cancer patients without available targeted therapies.
3. Cancer patients interested in a precise combination of herbal and conventional treatments.
Genome Integrity Testing:
This test uses cancer tissue samples to sequence regions encoding protein amino acid sequences, covering approximately 1.5% of the genome with sequencing depths typically exceeding 500X. This high depth of sequencing enables detection of most cancer-related genetic alterations and can also reveal some hereditary disease-related variations. Simultaneously conducting transcriptome sequencing of both cancerous and surrounding normal tissues provides a clearer view of the specific characteristics of the individual’s cancer, aiding in the formulation of more effective treatment strategies.
Target Audience for Genome Integrity Testing:
1. Cancer patients who wish to gain a more comprehensive view of their cancer’s genetic alterations beyond conventional tests (which typically analyze around 500 cancer-related genes) to enable more precise treatment and the potential for targeted herbal therapies.
2. Cancer patients without available targeted therapies.
3. Cancer patients interested in a precise combination of herbal and conventional therapies.
Cancer Transcriptome (or Expression Profile) Sequencing Explanation:
Cancer transcriptome (or expression profile) sequencing provides insights into the differences in genomic activity between cancerous and normal cells, highlighting cancer-specific gene expressions, unique RNA splicing patterns, cancer-specific fusion genes, cancer-associated microorganisms, and changes within the tumor microenvironment. These data are directly linked to treatment efficacy and patient survival. Our company sequences RNA from both cancer tissues and surrounding normal tissues, identifying case-specific cancer variations. Using prominent cancer databases, including the U.S. “Cancer Genome Atlas,” we identify survival-related genes and then apply our proprietary methods to pinpoint effective herbal medicines targeting these genes, offering recommendations for clinical use.
Target Audience for Cancer Transcriptome Sequencing Testing:
1. Patients who have previously undergone only cancer genome sequencing but achieved limited treatment results.
2. Patients seeking a more comprehensive understanding of their cancer genome to explore new treatment strategies for improved outcomes.
3. Patients interested in enhancing treatment with herbal medicine.
